{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:19:21Z","timestamp":1786551561058,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Australia Pty Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a paucity of information on the epidemiology of heart failure (HF) in Australia. The Study of Heart failure in the Australian Primary carE setting (SHAPE) study aims to estimate the prevalence and annual incidence of HF in the general Australian community and to describe the demographic and key clinical profile of Australians with HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook a retrospective cohort study based on analysis of non-identifiable medical records of adult patients cared for at 43 general practices between 1 July 2013 and 30 June 2018. Data were extracted from coded (diagnosis, pathology and prescription fields) and uncoded fields (clinical notes) in the medical records. The latter searches of free text looked for common synonyms relevant to HF. The population was stratified into three groups based on a hierarchy of selection criteria: (1) definite HF, (2) probable HF and (3) possible HF. The prevalence and annual incidence of HF were calculated, along with 95% confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The practices provided care to 2.3 million individual patients over the five-year study period, of whom 1.93 million were adults and 1.12 million were regular patients. Of these patients 15,468 were classified as having \u2018definite HF\u2019, 4751 as having \u2018probable HF\u2019 and 33,556 as having \u2018possible HF\u2019. A further 39,247 were identified as having an aetiological condition associated with HF.<\/jats:p>\n                    <jats:p>A formal HF diagnosis, HF terms recorded as text in the notes and HF-specific medication were the most common methods to identify \u2018definite\u2019 HF patients. Typical signs and symptoms in combination with a diuretic prescription was the most common method to identify \u2018probable HF\u2019 patients. The majority of \u2018possible\u2019 HF patients were identified by the presence of 2 or more of the typical signs or symptoms. Dyspnoea was the commonest recorded symptom and an elevated jugular venous pressure the commonest recorded sign.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This novel approach to undertaking retrospective research of primary care data successfully analysed a combination of coded and uncoded data from the electronic medical records of patients routinely managed in the GP setting. SHAPE is the first real-world study of the epidemiology of HF in the general Australian community setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-020-08781-8","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:02:55Z","timestamp":1589187775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The epidemiology of heart failure in the general Australian community - study of heart failure in the Australian primary carE setting (SHAPE): methods"],"prefix":"10.1186","volume":"20","author":[{"given":"Richard Whaddon","family":"Parsons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-9838","authenticated-orcid":false,"given":"A. Munro","family":"Neville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph G.","family":"Audehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Haikerwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Sindone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"8781_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12913-016-1748-0","volume":"16","author":"YK Chan","year":"2016","unstructured":"Chan YK, Tuttle C, Ball J, et al. Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue. BMC Health Serv Res. 2016;16:501.","journal-title":"BMC Health Serv Res"},{"key":"8781_CR2","volume-title":"Population Projections, Australia, 2012 to 2101 (cat. no. 3222.0)","author":"Australian Bureau of Statistics","year":"2013","unstructured":"Australian Bureau of Statistics, Population Projections, Australia, 2012 to 2101 (cat. no. 3222.0), 2013."},{"key":"8781_CR3","unstructured":"Scott I, Jackson C. Chronic heart failure management in Australia \u2013 time for general practice centred models of care: AFP; 2013;42(5):343-46."},{"key":"8781_CR4","unstructured":"British Medical Association 2018. International models of general practice. www.bma.org.uk\/-\/media\/files\/pdfs\/collective%20voice\/policy%20research\/nhs%20structure%20and%20delivery\/international-models-of-general-practice.pdf?la=en. Accessed 10 Nov 2019."},{"issue":"21","key":"8781_CR5","first-page":"S1","volume":"S89","author":"H Krum","year":"2012","unstructured":"Krum H, Best M, Tonkin A, et al. Prevalence of Heart Failure and Use of Beta-Blockers in Australian General Practice. Heart Lung Circ. 2012;S89(21):S1\u2013S142.","journal-title":"Heart Lung Circ"},{"key":"8781_CR6","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Cohen-Solal A, Cosin AJ. Management of heart failure in primary care (the IMPROVEMENT of heart failure Programme): an international survey. Lancet. 2002;360(9346):1631\u20139.","DOI":"10.1016\/S0140-6736(02)11601-1"},{"issue":"2","key":"8781_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5694\/j.1326-5377.2006.tb00479.x","volume":"185","author":"DK McInnes","year":"2006","unstructured":"McInnes DK, Saltman DC, Kidd MR. General practitioners\u2019 use of computers for prescribing and electronic health records: results from a national survey. Med J Aust. 2006;185(2):88\u201391.","journal-title":"Med J Aust"},{"key":"8781_CR8","volume-title":"General Practice: Health of the Nation","author":"The Royal Australian College of General Practitioners","year":"2017","unstructured":"The Royal Australian College of General Practitioners. General Practice: Health of the Nation. East Melbourne: RACGP; 2017."},{"key":"8781_CR9","unstructured":"Medical Director. www.medicaldirector.com\/help\/index.htm#t=kba%2Fclinical%2FAn_Overview_of_MedicalDirector_Clinical.htm. Accessed 1 Nov 2019."},{"key":"8781_CR10","volume-title":"National Heart Foundation of Australia and Cardiac Society of Australia and new Zealand guidelines for the prevention, detection and management of heart failure in Australia","author":"J Atherton","year":"2018","unstructured":"Atherton J, Sindone A, De Pasquale C, et al. National Heart Foundation of Australia and Cardiac Society of Australia and new Zealand guidelines for the prevention, detection and management of heart failure in Australia 2018."},{"key":"8781_CR11","volume-title":"Standards for general practices","author":"Royal Australian College of General Practitioners","year":"2017","unstructured":"Royal Australian College of General Practitioners. Standards for general practices. 5th ed. East Melbourne: RACGP; 2017.","edition":"5"},{"key":"8781_CR12","unstructured":"Pharmaceutical Benefits Scheme, 2019. www.pbs.gov.au\/medicine\/item\/8733P. Accessed 28 Oct 2019."},{"key":"8781_CR13","volume-title":"Deeble Institute Issues Brief No. 18: Reality check - reliable national data from general practice electronic health records emphasises the need to urgently address the lack of reliable national primary health data, particularly data from general practice","author":"J Gordon","year":"2016","unstructured":"Gordon J, Miller G, Britt H. Deeble Institute Issues Brief No. 18: Reality check - reliable national data from general practice electronic health records emphasises the need to urgently address the lack of reliable national primary health data, particularly data from general practice; 2016."},{"key":"8781_CR14","unstructured":"Department of Health, PIP QI Incentive guidance, 2019. https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/PIP-QI_Incentive_guidance. Accessed 11 Aug 2019."},{"issue":"3","key":"8781_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319.","journal-title":"Circ Heart Fail"},{"issue":"9","key":"8781_CR16","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1253\/circj.CJ-13-0971","volume":"77","author":"Y Sakata","year":"2013","unstructured":"Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77(9):2209.","journal-title":"Circ J"},{"key":"8781_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2019.06.055","volume-title":"A retrospective cohort study of heart failure in the Australian primary care setting (SHAPE) - clinical characteristics of HF patients","author":"Sindone","year":"2019","unstructured":"Sindone, Haikerwal, Audehm, et al. A retrospective cohort study of heart failure in the Australian primary care setting (SHAPE) - clinical characteristics of HF patients. Adelaide: CSANZ; 2019."},{"key":"8781_CR18","unstructured":"Australian Institute of Health and Welfare. Medicare-subsidised GP, allied health and specialist health care across local areas: 2013\u201314 to 2017\u201318. https:\/\/www.aihw.gov.au\/reports\/primary-health-care\/medicare-subsidised-gp-allied-health-and-specialis\/contents\/introduction. Accessed 20 Feb 2020."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08781-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-08781-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-08781-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T19:12:57Z","timestamp":1620673977000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-08781-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8781"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-08781-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17929\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17929\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17929\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17929\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"19 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Bellberry Human Research Ethics Committee (Application No: 2018\u201309-746). The Healius Clinical Council provided governance approval for the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Alphapharm, Aspen, AstraZeneca (AZ), Bayer, Biotronik, Boehringer Ingelheim, Bristol Myers Squibb, Janssen Cilag, Menarini, Merck Sharp and Dohme (MSD), Mylan, Novartis, Otsuka, Pfizer, Sanofi, Servier, Vifor. DH has given talks for AZ, Bayer, BMS, Novartis and Pfizer. PP has sat on advisory boards and\/or spoken at, facilitated or chaired at meetings for and\/or received travel and accommodation costs from AbbVie, Amgen, AZ, Bayer, BI, BMS, CSL, Eli Lilly, GSK, Janssen, Menarini, MSD, Novartis, Novo Nordisk, Pfizer, Sanofi & Seqirus. RA served as a member of several Advisory Boards and conducted paid presentations for AZ, Novartis and Sanofi in the past 2\u2009years, and Abbott, BMS, Eli Lilly, Novo Nordisk, Servier and Takeda prior to this. DL has received honoraria from: Amgen, AZ, Bayer, BI, BMS, Novartis, Pfizer, Sanofi and Shire. AusTrials was commissioned by Novartis Pharmaceuticals Australia Pty Ltd. to conduct the SHAPE study. AMN and RWP are both employees of AusTrials. KL is a full-time employee of Novartis Pharmaceuticals Australia Pty Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"648"}}